Position in ZTS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$125,134,918
-$249,190,639 QoQ
Shares Held
1,741,371
-45.0% QoQ
Ownership
0.421%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#47
of 1,408 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in ZTS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026RAYMOND JAMES FINANCIAL INC holds $625,710,198 across 33 Drug Manufacturers - Specialty & Generic names. ZTS ranks #1 (20.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
This page
|
1,741,371 | $125,134,918 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
580,170 | $97,781,849 | |
| 3 | HLN |
Haleon plc
|
7,278,875 | $67,911,902 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
2,383,479 | $58,657,416 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,692,660 | $57,347,317 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
55,173 | $29,894,385 | |
| 7 | VTRS |
Viatris Inc
|
1,668,730 | $26,499,430 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
234,788 | $26,047,378 |
All Filings in ZTS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $125,134,918 | 1,741,371 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $374,325,557 | 3,166,615 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $115,816,428 | 920,493 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $159,557,275 | 1,090,468 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $189,717,072 | 1,216,525 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $202,322,906 | 1,228,806 | Shares | Defined | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||